Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.

ABSTRACT: Melanoma incidence continues to rise at an alarming rate while effective systemic therapies remain very limited. Microphthalmia-associated transcription factor (MITF) is required for development of melanocytes and is an amplified oncogene in a fraction of human melanomas. Microphthalmia-associated transcription factor also plays an oncogenic role in human clear cell sarcomas, which typically exhibit melanoma-like features. Although pharmacologic suppression of MITF is of potential interest in a variety of clinical settings, it is not known to contain intrinsic catalytic activity capable of direct small molecule inhibition. An alternative drug-targeting strategy is to identify and interfere with lineage-restricted mechanisms required for its expression. Here, we report that multiple histone

SUBMITTER: Yokoyama S 

PROVIDER: S-EPMC3771662 | biostudies-literature | 2008 Aug

REPOSITORIES: biostudies-literature